8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors

Yuan, Qing; Wen, Min; Xu, Chang; Chen, A; Qiu, Ye-Bei; Cao, Jian-Guo; Zhang, Jian-Song; Song, Zhen-Wei

doi:10.7150/jca.30143



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(21):5244-5255. doi:10.7150/jca.30143 This issue Cite

Research Paper

8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors

Qing Yuan^1*, Min Wen^1*, Chang Xu^2,3, A Chen^2,3, Ye-Bei Qiu^2,3, Jian-Guo Cao^2,3, Jian-Song Zhang^1✉, Zhen-Wei Song^1,2,3✉

1. Department of preclinical medicine, Medical College, Hunan Normal University, Changsha, 410013, China
2. Department of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China
3. Key Laboratory of Study and Discover of Small Targeted Molecules of Hunan Province, Changsha 410013, China
* They contributed equally to this work.

Citation:

Yuan Q, Wen M, Xu C, Chen A, Qiu YB, Cao JG, Zhang JS, Song ZW. 8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors. J Cancer 2019; 10(21):5244-5255. doi:10.7150/jca.30143. https://www.jcancer.org/v10p5244.htm

Other styles

Abstract

We have previously reported that 8-bromo-7-methoxychrysin (BrMC), a novel synthetic derivative of chrysin, was demonstrated anti-tumor activities against several human cancers, including lung cancer. Interaction between inflammation and cancer stem cell are recently increasingly recognized in tumorigenesis and progression. The purpose of this study was to investigate whether BrMC inhibits lung cancer stemness of H460 cells induced by inflammatory factors (TGF-β combined with TNF-α) and its potential mechanism. Our results showed that BrMC inhibited lung cancer stemness, as validated by enhanced self-renewal ability, higher in vitro tumorigenicity, and increased expression of CD133, CD44, Bmi1 and Oct4 in H460 cells administered TNF-α after prolonged induction by TGF-β, in a concentration-dependent manner. Both NF-κB inhibition by SN50 and FoxM1 suppression by thiostrepton (THI) prompted the inhibition of BrMC on lung CSCs. Conversely, overexpression of NF-κBp65 significantly antagonized the above effects of BrMC. Meanwhile, overexpression of FoxM1 also significantly compromised BrMC function on suppression of FoxM1 and NF-κBp65 as well as stemness of lung CSCs. Our results suggest that activation of NF-κB and FoxM1 by cytokines facilitate the acquisition CSCs phenotype, and compromise the chemical inhibition, which may represent an effective therapeutic target for treatment of human lung cancer. Moreover, BrMC may be a potential promising candidate for targeting NF-κB/ FoxM1 to prevent the tumorigenesis under inflammatory microenvironment.

Keywords: lung cancer, cancer stem cell, tumorigenesis, inflammatory factor, NF-κB, FoxM1

Citation styles

APA

Yuan, Q., Wen, M., Xu, C., Chen, A., Qiu, Y.B., Cao, J.G., Zhang, J.S., Song, Z.W. (2019). 8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors. Journal of Cancer, 10(21), 5244-5255. https://doi.org/10.7150/jca.30143.

ACS

Yuan, Q.; Wen, M.; Xu, C.; Chen, A.; Qiu, Y.B.; Cao, J.G.; Zhang, J.S.; Song, Z.W. 8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors. J. Cancer 2019, 10 (21), 5244-5255. DOI: 10.7150/jca.30143.

NLM

CSE

Yuan Q, Wen M, Xu C, Chen A, Qiu YB, Cao JG, Zhang JS, Song ZW. 2019. 8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors. J Cancer. 10(21):5244-5255.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.